View in EDS

Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial.

Saved in:
Bibliographic Details
Title: Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial.
Authors: Garon EB; Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California. Electronic address: egaron@mednet.ucla.edu., Spira AI; Co-Director, Virginia Cancer Specialists Research Institute and NEXT Oncology, Fairfax, Virginia., Goldberg SB; Department of Internal Medicine, Yale Cancer Center, New Haven, Connecticut., Chaft JE; Department of Medicine, Weill Cornell Medical College and Memorial Sloan-Kettering Cancer Center, New York, New York., Papadimitrakopoulou V; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Cascone T; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Antonia SJ; H. Lee Moffitt Cancer Center, Tampa, Florida., Brahmer JR; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland., Camidge DR; Department of Medicine-Medical Oncology, University of Colorado Cancer Center, Denver, Colorado., Powderly JD; Carolina BioOncology Institute, Huntersville, North Carolina., Wozniak AJ; Department of Medicine, University of Pittsburgh Hillman Cancer Center, Pittsburgh, Pennsylvania., Felip E; Deparmtent of Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Wu S; Oncology Research and Development, AstraZeneca, Gaithersburg, Maryland., Ascierto ML; Oncology Research and Development, AstraZeneca, Gaithersburg, Maryland., Elgeioushi N; Oncology Research and Development, AstraZeneca, Gaithersburg, Maryland., Awad MM; Dana-Farber Cancer Institute, Boston, Massachusetts.
Source: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2023 Aug; Vol. 18 (8), pp. 1094-1102. Date of Electronic Publication: 2023 May 04.
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101274235 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1556-1380 (Electronic) Linking ISSN: 15560864 NLM ISO Abbreviation: J Thorac Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37146752
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Garon+EB%22">Garon EB</searchLink>; Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California. Electronic address: egaron@mednet.ucla.edu.<br /><searchLink fieldCode="AU" term="%22Spira+AI%22">Spira AI</searchLink>; Co-Director, Virginia Cancer Specialists Research Institute and NEXT Oncology, Fairfax, Virginia.<br /><searchLink fieldCode="AU" term="%22Goldberg+SB%22">Goldberg SB</searchLink>; Department of Internal Medicine, Yale Cancer Center, New Haven, Connecticut.<br /><searchLink fieldCode="AU" term="%22Chaft+JE%22">Chaft JE</searchLink>; Department of Medicine, Weill Cornell Medical College and Memorial Sloan-Kettering Cancer Center, New York, New York.<br /><searchLink fieldCode="AU" term="%22Papadimitrakopoulou+V%22">Papadimitrakopoulou V</searchLink>; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Cascone+T%22">Cascone T</searchLink>; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Antonia+SJ%22">Antonia SJ</searchLink>; H. Lee Moffitt Cancer Center, Tampa, Florida.<br /><searchLink fieldCode="AU" term="%22Brahmer+JR%22">Brahmer JR</searchLink>; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.<br /><searchLink fieldCode="AU" term="%22Camidge+DR%22">Camidge DR</searchLink>; Department of Medicine-Medical Oncology, University of Colorado Cancer Center, Denver, Colorado.<br /><searchLink fieldCode="AU" term="%22Powderly+JD%22">Powderly JD</searchLink>; Carolina BioOncology Institute, Huntersville, North Carolina.<br /><searchLink fieldCode="AU" term="%22Wozniak+AJ%22">Wozniak AJ</searchLink>; Department of Medicine, University of Pittsburgh Hillman Cancer Center, Pittsburgh, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Felip+E%22">Felip E</searchLink>; Deparmtent of Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Wu+S%22">Wu S</searchLink>; Oncology Research and Development, AstraZeneca, Gaithersburg, Maryland.<br /><searchLink fieldCode="AU" term="%22Ascierto+ML%22">Ascierto ML</searchLink>; Oncology Research and Development, AstraZeneca, Gaithersburg, Maryland.<br /><searchLink fieldCode="AU" term="%22Elgeioushi+N%22">Elgeioushi N</searchLink>; Oncology Research and Development, AstraZeneca, Gaithersburg, Maryland.<br /><searchLink fieldCode="AU" term="%22Awad+MM%22">Awad MM</searchLink>; Dana-Farber Cancer Institute, Boston, Massachusetts.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101274235%22">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</searchLink> [J Thorac Oncol] 2023 Aug; Vol. 18 (8), pp. 1094-1102. <i>Date of Electronic Publication: </i>2023 May 04.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101274235 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1556-1380 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215560864%22">15560864 </searchLink><i>NLM ISO Abbreviation: </i>J Thorac Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37146752
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.jtho.2023.04.020
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1094
    Titles:
      – TitleFull: Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Garon EB
      – PersonEntity:
          Name:
            NameFull: Spira AI
      – PersonEntity:
          Name:
            NameFull: Goldberg SB
      – PersonEntity:
          Name:
            NameFull: Chaft JE
      – PersonEntity:
          Name:
            NameFull: Papadimitrakopoulou V
      – PersonEntity:
          Name:
            NameFull: Cascone T
      – PersonEntity:
          Name:
            NameFull: Antonia SJ
      – PersonEntity:
          Name:
            NameFull: Brahmer JR
      – PersonEntity:
          Name:
            NameFull: Camidge DR
      – PersonEntity:
          Name:
            NameFull: Powderly JD
      – PersonEntity:
          Name:
            NameFull: Wozniak AJ
      – PersonEntity:
          Name:
            NameFull: Felip E
      – PersonEntity:
          Name:
            NameFull: Wu S
      – PersonEntity:
          Name:
            NameFull: Ascierto ML
      – PersonEntity:
          Name:
            NameFull: Elgeioushi N
      – PersonEntity:
          Name:
            NameFull: Awad MM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: 2023 Aug
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1556-1380
          Numbering:
            – Type: volume
              Value: 18
            – Type: issue
              Value: 8
          Titles:
            – TitleFull: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
              Type: main
ResultId 1